Regulatory Approval
Lupin Receives USFDA Approval for Dapagliflozin + Metformin Combination Tablets
NSE
lupin
BSE
500257
Lupin has received USFDA approval for its Dapagliflozin and Metformin Hydrochloride Extended-Release tablets, strengthening its diabetes portfolio in the U.S., along with a tentative approval for an additional dosage variant.
PRICE-SENSITIVE TRIGGER
Event: USFDA approval for combination drug
Type: Regulatory Approval
Impact: Positive
Immediate Effect: Expands product portfolio in U.S. generics market
What Happened ?
Lupin Limited announced that it has received approval from the U.S. Food and Drug Administration (USFDA) for its Dapagliflozin and Metformin Hydrochloride Extended-Release tablets in multiple dosage strengths.
Additionally, the company received tentative approval for another dosage variant.
The approved product is bioequivalent to Xigduo® XR, a widely used diabetes treatment.
Key details
Product Details
- Combination drug: Dapagliflozin + Metformin ER
- Approved strengths:
- 5 mg/500 mg
- 5 mg/1000 mg
- 10 mg/500 mg
- 10 mg/1000 mg
- Tentative approval: 2.5 mg/1000 mg
Strategic Importance
- Strengthens presence in diabetes segment
- Expands U.S. generics portfolio
- Targets chronic therapy market
Market Positioning
- Bioequivalent to Xigduo XR (AstraZeneca)
- Addresses growing diabetes prevalence
Business Impact
- Enhances product pipeline
- Improves revenue diversification
- Strengthens foothold in U.S. market
Risk Analysis
Key Risks
- Pricing pressure in U.S. generics market
- Competition from other generic players
- Margin compression
Worst Case Scenario
Limited market share due to competition
Risk Level: Medium
Company Commentary
- Expanding diabetes product portfolio
- Strengthening global generics presence
- Focus on chronic therapies
Official Exchange Filing: Lupin Limited